Archivio istituzionale della ricerca dell'Università degli Studi di Palermo

INCORVAIA, Lorena
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.034
EU - Europa 1.510
AS - Asia 332
SA - Sud America 11
Continente sconosciuto - Info sul continente non disponibili 3
OC - Oceania 2
Totale 6.892
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.020
IT - Italia 583
CN - Cina 242
FI - Finlandia 179
UA - Ucraina 133
GB - Regno Unito 116
IE - Irlanda 106
DE - Germania 92
BE - Belgio 81
RU - Federazione Russa 52
SE - Svezia 49
RO - Romania 39
PL - Polonia 24
IN - India 18
FR - Francia 14
HK - Hong Kong 14
IR - Iran 14
CA - Canada 12
NL - Olanda 10
KR - Corea 9
JP - Giappone 8
TR - Turchia 8
AT - Austria 7
BG - Bulgaria 6
CH - Svizzera 6
ES - Italia 4
AE - Emirati Arabi Uniti 3
BR - Brasile 3
CY - Cipro 3
EU - Europa 3
PE - Perù 3
AL - Albania 2
AR - Argentina 2
AU - Australia 2
CL - Cile 2
DK - Danimarca 2
GR - Grecia 2
MX - Messico 2
NO - Norvegia 2
TW - Taiwan 2
UZ - Uzbekistan 2
BD - Bangladesh 1
EC - Ecuador 1
IL - Israele 1
KH - Cambogia 1
KW - Kuwait 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LT - Lituania 1
PH - Filippine 1
SA - Arabia Saudita 1
SG - Singapore 1
Totale 6.892
Salva come PNG Salva come JPEG
Città #
Fairfield 826
Chandler 578
Woodbridge 424
Houston 412
Wilmington 318
Ashburn 310
Seattle 299
Ann Arbor 278
Cambridge 256
Palermo 177
Medford 132
Dublin 103
Altamura 89
Des Moines 87
Princeton 87
Brussels 81
San Diego 75
Lawrence 71
Jacksonville 68
Nanjing 50
Boardman 34
Bremen 34
Boydton 33
Dearborn 33
London 29
Jinan 26
Changsha 24
Tulsa 24
Helsinki 21
Shenyang 17
Beijing 16
Chicago 15
Falls Church 15
Aversa 14
Kumar 14
Nanchang 13
Milan 12
Hebei 10
Jiaxing 10
Phoenix 10
Redwood City 10
Tehran 10
Tianjin 10
Central 9
Izmir 8
Ningbo 8
Saint Petersburg 8
San Mateo 8
San Paolo di Civitate 8
Orange 7
Seelze 7
Seongnam 7
Edinburgh 6
Norwalk 6
Rome 6
Taiyuan 6
Toronto 6
Auburn Hills 5
Guangzhou 5
Haikou 5
Hanover 5
Islington 5
Lucera 5
Moscow 5
Sofia 5
Turin 5
Zhengzhou 5
Amsterdam 4
Florence 4
Frankfurt am Main 4
Fuzhou 4
Kunming 4
Naples 4
Partanna 4
Verona 4
Vienna 4
Bari 3
Cagliari 3
Casteltermini 3
Frankfurt Am Main 3
Hangzhou 3
Lanzhou 3
Lima 3
Limassol 3
Los Angeles 3
Osio Sotto 3
Reggio Emilia 3
Tokyo 3
Venice 3
Aci Sant'antonio 2
Agrigento 2
Alcamo 2
Atlanta 2
Bagheria 2
Bologna 2
Cattolica 2
Chiswick 2
Clearwater 2
Copenhagen 2
Council Bluffs 2
Totale 5.402
Salva come PNG Salva come JPEG
Nome #
Analysis of tissue and circulating microRNA expression during metaplastic transformation of the esophagus 188
Gastrointestinal stromal tumors (GISTs): focus on histopathological diagnosis and biomolecular features 186
One shot NEPA plus dexamethasone to prevent multiple-day chemotherapy in sarcoma patients 186
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial 181
Monitoring blood biomarkers to predict nivolumab effectiveness in NSCLC patients 181
Denosumab for bone health in prostate and breast cancer patients receiving endocrine therapy? A systematic review and a meta-analysis of randomized trials 177
Liquid Biopsy in Breast Cancer 172
Triple negative breast cancer: Shedding light onto the role of pi3k/akt/mtor pathway 156
How to Deal with Second Line Dilemma in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis 149
Activin A circulating levels in patients with bone metastasis from breast or prostate cancer 147
Prognostic significance of circulating PD-1, PD-L1, pan-BTN3As, BTN3A1 and BTLA in patients with pancreatic adenocarcinoma 147
"Back to a false normality": New intriguing mechanisms of resistance to PARP inhibitors 145
Beyond evidence-based data: Scientific rationale and tumor behavior to drive sequential and personalized therapeutic strategies for the treatment of metastatic renal cell carcinoma 143
Metastatic site location influences the diagnostic accuracy of ctDNA EGFR- mutation testing in NSCLC patients: a pooled analysis 143
Serum follistatin in patients with prostate cancer metastatic to the bone 142
Antiemetic prophylaxis containing Palonosetron (P) alone or in combination with Aprepitant (A) in the treatment of advanced soft tissue sarcoma (STS) patients with epirubicin and ifosfamide 136
Clinical Impact of Cystatin C/Cathepsin L and Follistatin/Activin A Systems in Breast Cancer Progression: A Preliminary Report 134
Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC) 128
Looking for the best immune-checkpoint inhibitor in pre-treated NSCLC patients: An indirect comparison between nivolumab, pembrolizumab and atezolizumab 127
Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a step toward a biomarker for therapeutic decisions 126
Personalization of regorafenib treatment in metastatic gastrointestinal stromal tumours in real-life clinical practice 120
Activity and safety of temozolomide in advanced adrenocortical carcinoma patients 119
Surgical treatment of primary gastrointestinal stromal tumors (GISTs): Management and prognostic role of R1 resections 116
The resistance related to targeted therapy in malignant pleural mesothelioma: Why has not the target been hit yet? 112
Can the plasma PD-1 levels predict the presence and efficiency of tumor-infiltrating lymphocytes in patients with metastatic melanoma? 110
Detection of RAS mutations in circulating tumor DNA: a new weapon in an old war against colorectal cancer. A systematic review of literature and meta-analysis 106
Role of tumor-infiltrating lymphocytes in patients with solid tumors: Can a drop dig a stone? 103
Molecular profiling of pancreatic neuroendocrine tumors (pNETS) and the clinical potential 97
Liquid Biopsy in Gynecological Cancers 94
MMP-2, MMP-9 and activin A blood levels in patients with breast cancer or prostate cancer metastatic to the bone. 93
Soft tissue sarcomas in the precision medicine era: new advances in clinical practice and future perspectives 87
Detection of Germline Mutations in a Cohort of 139 Patients with Bilateral Breast Cancer by Multi-Gene Panel Testing: Impact of Pathogenic Variants in Other Genes beyond BRCA1/2 86
New potential circulating markers for the therapeutic monitoring of metastatic bone disease. 83
Liquid Biopsy in Gastrointestinal Stromal Tumor 82
Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives 81
Studio del pattern di distribuzione dell'Activina A nel siero di pazienti con metastasi ossee da carcinoma prostatico in trattamento con acido zoledronico 80
Activin A and matrix metalloproteinase -2 and -9 blood levels as gauges of bone metastatic spread 79
Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors following progression with imatinib, sunitinib and regorafenib 78
BRCA1/2 pathogenic variants in triple-negative versus luminal-like breast cancers: genotype–phenotype correlation in a cohort of 531 patients 78
Lenograstim in preventing chemotherapy-induced febrile neutropenia in patients with soft tissue sarcoma 77
Hereditary breast and ovarian cancer in families from southern Italy (Sicily)—Prevalence and geographic distribution of pathogenic variants in BRCA1/2 genes 77
Are Long Noncoding RNAs New Potential Biomarkers in Gastrointestinal Stromal Tumors (GISTs)? The Role of H19 and MALAT1 75
ACTIVIN A CIRCULATING LEVELS IN PATIENTS WITH PRIMARY OSTEOPOROSIS OR BONE METASTASES FROM BREAST CANCER 73
Effects of zoledronic acid on proteinase plasma levels in patients with bone metastases. 72
A “lymphocyte microrna signature” as predictive biomarker of immunotherapy response and plasma pd-1/pd-l1 expression levels in patients with metastatic renal cell carcinoma: Pointing towards epigenetic reprogramming 72
Correction to: One shot NEPA plus dexamethasone to prevent chemotherapy-induced nausea and vomiting (CINV) in sarcoma patients receiving multiple-day chemotherapy (Supportive Care in Cancer, (2019), 27, 9, (3593-3597), 10.1007/s00520-019-4645-3) 70
Activin A circulating levels in Patients with primary osteoporosis or bone metastases from brest cancer 68
Effects of Zoledronic Acid on Cathepsin K circulating levels in patients with bone metastasis. 68
Non-Small Cell Lung Cancer Harboring Concurrent EGFR Genomic Alterations: A Systematic Review and Critical Appraisal of the Double Dilemma 68
Activin A circulating levels in patients with osteoporosis or bone metastasis from breast cancer 67
Recent advances in desmoid tumor therapy 65
Real-world data on cabozantinib in previously treated patients with metastatic renal cell carcinoma: Focus on sequences and prognostic factors 63
Impact of Chemotherapy in the Adjuvant Setting of Early Stage Uterine Leiomyosarcoma: A Systematic Review and Updated Meta-Analysis 63
Into the wild of long non-coding RNA in gastrointestinal stromal tumors (GISTs) to explore new prognostic/predictive biomarkers 62
How do skeletal morbidity rate and special toxicities affect 12-week versus 4-week schedule zoledronic acid efficacy? A systematic review and a meta-analysis of randomized trials 62
Potential miRNAs involved in molecular pathways mediating the anticancer effects of short term starvation in breast cancer cells treated with doxorubicin 60
null 59
Can the plasma PD-1 levels predict the presence and efficiency of tumor-infiltrating lymphocytes in metastatic melanoma patients? 52
Monoclonal antibodies for the treatment of non-hematological tumors: a safety review 50
Clinical significance of Activin A serum levels in patients with primary osteoporosis: a preliminary report 49
Challenges and advances for the treatment of renal cancer patients with brain metastases: From immunological background to upcoming clinical evidence on immune-checkpoint inhibitors 49
null 47
Body mass index as a risk factor for toxicities in patients with advanced soft-tissue sarcoma treated with trabectedin 47
I tumori stromali gastrointestinali: dalla biologia alla clinica 44
Assessment of morphological CT imaging features for the prediction of risk stratification, mutations, and prognosis of gastrointestinal stromal tumors 44
Type and gene location of kit mutations predict progression-free survival to first-line imatinib in gastrointestinal stromal tumors: A look into the exon 40
Cancer of the Thyroid 40
Safety and effectiveness of gemcitabine for the treatment of classic Kaposi’s sarcoma without visceral involvement 39
Prevalence and Spectrum of Germline BRCA1 and BRCA2 Variants of Uncertain Significance in Breast/Ovarian Cancer: Mysterious Signals From the Genome 38
Not all KIT 557/558 codons mutations have the same prognostic influence on recurrence-free survival: breaking the exon 11 mutations in gastrointestinal stromal tumors (GISTs) 37
Impact of deleterious variants in other genes beyond BRCA1/2 detected in breast/ovarian and pancreatic cancer patients by NGS-based multi-gene panel testing: looking over the hedge 37
Prognostic role of plasma pd‐1, pd‐l1, pan‐btn3as and btn3a1 in patients affected by metastatic gastrointestinal stromal tumors: Can immune checkpoints act as a sentinel for short‐term survival? 37
Arterial Stiffness: Effects of Anticancer Drugs Used for Breast Cancer Women 36
Nivolumab VERSUS Cabozantinib as Second-Line Therapy in Patients With Advanced Renal Cell Carcinoma: A Real-World Comparison 36
Deep Learning Networks for Automatic Retroperitoneal Sarcoma Segmentation in Computerized Tomography 35
Cabozantinib in Patients with Advanced Renal Cell Carcinoma Primary Refractory to First-line Immunocombinations or Tyrosine Kinase Inhibitors 32
The molecular profiling of solid tumors by liquid biopsy: a position paper of the AIOM–SIAPEC-IAP–SIBioC–SIC–SIF Italian Scientific Societies 31
Cabozantinib in Pretreated Patients with Metastatic Renal Cell Carcinoma with Sarcomatoid Differentiation: A Real-World Study 31
Body mass index in patients treated with cabozantinib for advanced renal cell carcinoma: A new prognostic factor? 30
Clinical Potential of Circulating Cell-Free DNA (cfDNA) for Longitudinally Monitoring Clinical Outcomes in the First-Line Setting of Non-Small-Cell Lung Cancer (NSCLC): A Real-World Prospective Study 26
S-Adenosylmethionine Supplementation May Reduce Cancer-Related Fatigue: A Prospective Evaluation Using the FACIT-F Questionnaire in Colon Cancer Patients Undergoing Oxaliplatin-Based Chemotherapy Regimens 25
Navigating the liquid biopsy Minimal Residual Disease (MRD) in non-small cell lung cancer: Making the invisible visible 24
Body mass index and baseline platelet count as predictive factors in Merkel cell carcinoma patients treated with avelumab 23
The Evolving Scenario in the Assessment of Radiological Response for Hepatocellular Carcinoma in the Era of Immunotherapy: Strengths and Weaknesses of Surrogate Endpoints 23
Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies 23
SIRM-SIN-AIOM: appropriateness criteria for evaluation and prevention of renal damage in the patient undergoing contrast medium examinations—consensus statements from Italian College of Radiology (SIRM), Italian College of Nephrology (SIN) and Italian Association of Medical Oncology (AIOM) 23
The tumor-agnostic treatment for patients with solid tumors: a position paper on behalf of the AIOM- SIAPEC/IAP-SIBioC-SIF Italian Scientific Societies 21
The diagnostic accuracy of PIK3CA mutations by circulating tumor DNA in breast cancer: an individual patient data meta-analysis 20
Standard versus personalized schedule of regorafenib in metastatic gastrointestinal stromal tumors: a retrospective, multicenter, real-world study 20
Prognostic role of soluble PD-1 and BTN2A1 in overweight melanoma patients treated with nivolumab or pembrolizumab: finding the missing links in the symbiotic immune-metabolic interplay 18
Get up, stand up: Alongside adolescents and young adults with cancer for their right to be forgotten 17
The challenge of the Molecular Tumor Board empowerment in clinical oncology practice: A Position Paper on behalf of the AIOM- SIAPEC/IAP-SIBioC-SIC-SIF-SIGU-SIRM Italian Scientific Societies 16
The molecular tumor board: a tool for the governance of precision oncology in the real world 16
Higher Incidence of Cancer Therapy-Related Cardiac Dysfunction in the COVID-19 Era: A Single Cardio-Oncology Center Experience 15
Exploring the Dynamic Crosstalk between the Immune System and Genetics in Gastrointestinal Stromal Tumors 14
Immunological Aspects of Von Hippel-Lindau Disease: A Focus on Neuro-Oncology and Myasthenia Gravis 13
Current treatment options for HER2-positive breast cancer patients with brain metastases 13
Tumor markers in urogynaecological tumors. 12
Healthcare Professional Communication on Sexual Health: A Report from the Italian Working Group on Adolescents and Young Adults with Cancer 11
Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group? 11
Totale 7.384
Salva come PNG Salva come JPEG
Categoria #
all - tutte 24.197
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 24.197
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019426 0 0 17 12 7 25 39 12 12 38 131 133
2019/20201.755 142 72 124 260 169 224 163 114 137 130 165 55
2020/20211.332 61 51 100 93 183 87 101 92 146 162 157 99
2021/20221.264 87 186 59 28 53 70 55 69 113 162 166 216
2022/20231.783 170 306 37 217 160 245 101 156 180 42 104 65
2023/2024293 53 141 99 0 0 0 0 0 0 0 0 0
Totale 7.473